The purpose of this paper is to review pre-clinical evidence surrounding the use of MIA-602 and discuss the potential for new targeted hormone therapies based on GHRH-R antagonism in the treatment of AML. This evidence concerns the gene GHRHR and acute myeloid leukemia.